Teratogenic exposures

American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

Volumn 157, Issue 3, 2011, Pages 150-169

  Običan, Sarah ^a   Scialli, Anthony R ^b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Toxicology Center   (Canada)

Author keywords

Angiotensin converting enzyme inhibitors; Carbamzepine; Diethylstilbestrol; Ethanol; Isotretinoin; Lithium; Methimazole; Misoprostol; Mycophenolate mofetil; Penicillamine; Phenytoin; Rubella; Teratogenic exposures; Thalidomide; Toluene; Valproic acid; Varicella; Warfarin; X ray

Indexed keywords

ALCOHOL; AMINOPTERIN; CAPTOPRIL; CARBAMAZEPINE; CARBIMAZOLE; CHEMICAL TERATOGEN; DIETHYLSTILBESTROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETRETIN; ETRETINATE; ISOTRETINOIN; LAMOTRIGINE; LITHIUM; LIVE VACCINE; METHOTREXATE; MIFEPRISTONE; MISOPROSTOL; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PHENOBARBITAL; PHENYTOIN; RUBELLA VACCINE; THALIDOMIDE; THIAMAZOLE; TOLUENE; TOPIRAMATE; VALPROIC ACID; WARFARIN;

ACNE CYSTICA; ALCOHOLISM; ANENCEPHALUS; ANGIOGENESIS; ANOTIA; ANURIA; AORTA ANOMALY; ARTHROGRYPOSIS; ARTHROPATHY; ARTICLE; BIPOLAR DISORDER; BIRTH DEFECT; BLOOD PRESSURE; BONE MALFORMATION; BRAIN MALFORMATION; BRAIN NECROSIS; CATARACT; CENTRAL NERVOUS SYSTEM MALFORMATION; CHICKEN; CHICKENPOX; CLEFT LIP; CLEFT PALATE; CLUBFOOT; COLOBOMA; COMBINATION CHEMOTHERAPY; CONDUCTION DEAFNESS; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CONNECTIVE TISSUE DISEASE; CORPUS CALLOSUM AGENESIS; CRANIAL NEUROPATHY; CRANIOFACIAL MALFORMATION; CRANIOFACIAL SYNOSTOSIS; CRYPTORCHISM; CYSTINURIA; CYTOMEGALOVIRUS INFECTION; DEVELOPMENTAL DISORDER; DIAPHRAGM HERNIA; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG STRUCTURE; DRUG WITHDRAWAL; DUODENOUM ATRESIA; DUODENUM DISEASE; EAR MALFORMATION; EBSTEIN ANOMALY; ECTOPIC KIDNEY; ECTOPIC PREGNANCY; ELECTROMAGNETIC RADIATION; EMBRYOPATHY; EMBRYOTOXICITY; EPICANTHUS; EPIDIDYMAL CYST; EPILEPSY; ERYTHEMA NODOSUM LEPROSUM; ESOPHAGUS ATRESIA; EXPERIMENTAL MOUSE; EXPERIMENTAL RABBIT; EXPERIMENTAL RAT; EXTERNAL EAR MALFORMATION; EYE MALFORMATION; FACE DEFORMITY; FACE MALFORMATION; FACIAL CLEFT; FACIAL HEMANGIOMATA; FACIAL NERVE PARALYSIS; FALLOT TETRALOGY; FEMALE GENITAL TRACT MALFORMATION; FETAL ALCOHOL SYNDROME; FETAL HYDANTOIN SYNDROME; FETOTOXICITY; FETUS BLOOD PRESSURE; FETUS DEATH; FETUS DEVELOPMENT; FETUS DISEASE; FETUS MALFORMATION; FINGER MALFORMATION; FIRST TRIMESTER PREGNANCY; GROWTH RETARDATION; HAIR DISEASE; HEART ARRHYTHMIA; HEART ATRIUM SEPTUM DEFECT; HEART VALVE PROSTHESIS; HEART VENTRICLE SEPTUM DEFECT; HEPATOSPLENOMEGALY; HERPES SIMPLEX; HUMAN; HYDRAMNIOS; HYDROCEPHALUS; HYDRONEPHROSIS; HYDROPS; HYPERTELORISM; HYPERTHYROIDISM; HYPOCALVARIA; HYPOSPADIAS; HYPOTENSION; INFERTILITY; INGUINAL HERNIA; INTELLIGENCE QUOTIENT; INTESTINE MALROTATION; INTRAUTERINE GROWTH RETARDATION; IONIZING RADIATION; JAUNDICE; JOINT HYPERFLEXIBILITY; JOINT MALFORMATION; KIDNEY AGENESIS; KIDNEY DYSPLASIA; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY MALFORMATION; LAX SKIN; LIMB DEFECT; LIMB MALFORMATION; LISTERIOSIS; LOW BIRTH WEIGHT; LOW DRUG DOSE; LOW SET EAR; LUMBAR MENINGOMYELOCELE; LUNG HYPOPLASIA; MEASLES; MENINGOMYELOCELE; MENTAL DEFICIENCY; MENTAL DEVELOPMENT; MEROMELIA; MICROCEPHALY; MICROGNATHIA; MICROPHTHALMIA; MICROTIA; MIGRAINE; MONOTHERAPY; MOTOR DEVELOPMENT; MOUTH MALFORMATION; MULTIPLE MYELOMA; MUSCLE HYPOTONIA; NAIL DISEASE; NECK MALFORMATION; NEOPLASM; NEUROBLASTOMA; NEUROECTODERM TUMOR; NONHUMAN; NOSE HYPOPLASIA; NOSE MALFORMATION; OCCUPATIONAL EXPOSURE; OLIGOHYDRAMNIOS; OPTIC NERVE ATROPHY; ORCHITIS; PALATE MALFORMATION; PARVOVIRUS INFECTION; PATENT DUCTUS ARTERIOSUS; PETECHIA; PHALANX HYPOPLASIA; PHOCOMELIA; PLACENTAL TRANSFER; POLYDACTYLY; POSTPARTUM HEMORRHAGE; PREMATURE LABOR; PREMATURITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PSORIASIS; PULMONARY VALVE STENOSIS; RADIATION DOSE; RADIUS APLASIA; RHEUMATOID ARTHRITIS; RIB MALFORMATION; RISK ASSESSMENT; RUBELLA; SACRAL DIMPLE; SCALP MALFORMATION; SEIZURE; SHORT NOSE; SIDE EFFECT; SKIN APLASIA; SKIN MALFORMATION; SKULL MALFORMATION; SPATIAL ORIENTATION; SPINA BIFIDA; SPONTANEOUS ABORTION; STOMACH ULCER; SYNDACTYLY; SYPHILIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENESIS; TERATOGENICITY; TETHERED FORESKIN; THIRD TRIMESTER PREGNANCY; THROMBOCYTOPENIA; THUMB MALFORMATION; THYMUS DISEASE; THYMUS MALFORMATION; THYROID DISEASE; TOOTH MALFORMATION; TOXOPLASMOSIS; TRACHEOESOPHAGEAL FISTULA; TREATMENT WITHDRAWAL; TRIGEMINUS NEURALGIA; UMBILICAL HERNIA; UROGENITAL TRACT MALFORMATION; UTERUS CERVIX MALFORMATION; UTERUS HYPOPLASIA; UTERUS MALFORMATION; VAGINA ADENOCARCINOMA; VAGINA CARCINOMA; VERTEBRA MALFORMATION; VISION; WILSON DISEASE; WOUND HEALING IMPAIRMENT;

RUBELLA;

EID: 79960561020     PISSN: 15524868     EISSN: 15524876     Source Type: Journal    
DOI: 10.1002/ajmg.c.30310     Document Type: Article

References (208)

1. Abel EL. 1995. An update on incidence of FAS: FAS is not an equal opportunity birth defect. Neurotoxicol Teratol 17: 437-443.
2. Adam M, Manning M, Beck A, Kwan A, Enns GM, Clericuzio C, Hoyme HE. 2003. Methotrexate/misoprostol embryopathy: Report of four cases resulting from failed medical abortion. Am J Med Genet Part A 123A: 72-78.
3. Adams J. 2004. The adverse effect profile of neurobehavioral teratogens: Retinoic acid. Birth Defects Res Part A Clin Mol Teratol 70: 279.
4. Adams J, Lammer EJ. 1993. Neurobehavioral teratology of isotretinoin. Reprod Toxicol 7: 175-177.
5. Alkalay AL, Pomerance JJ, Rimoin DL. 1987. Fetal varicella syndrome. J Pediatr 111: 320-323.
6. American College of Obstetricians and Gynecologists. 2004. Guidelines for diagnostic imaging during pregnancy. Committee Opinion number 299. Washington, DC: American College of Obstetricians and Gynecologists.
7. Barbero P, Valdez R, Rodríuez H, Tiscornia C, Mansilla E, Allons A, Coll S, Liascovich R. 2008. Choanal atresia associated with maternal hyperthyroidism treated with methimazole: A case-control study. Am J Med Genet Part A 146A: 2390-2395.
8. Bavnick JN, Weaver DD. 1986. Subclavian artery supply disruption sequence: Hypothesis of a vascular etiology for Poland, Klippel-Feil and Mobius anomalies. Am J Med Genet 23: 903-918.
9. Bérard A, Azoulay L, Koren G, Blais L, Perreault S, Oraichi D. 2007. Isotretinoin pregnancies, abortions and birth defects: A population-based perspective. Br J Clin Pharmacol 63: 196-205.
10. Bertollini R, Källen B, Mastroiacovo P, Robert E. 1987. Anticonvulsant drugs in monotherapy. Effect on the fetus. Eur J Epidemiol 3: 164-171.
11. Binkerd PE, Rowland JM, Nau H, Hendrickx AG. 1988. Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. Fundam Appl Toxicol 11: 485-493.
12. Bjerkedal T, Czeizel A, Gouiard J, Källén B, Mastroiacova P, Nevin N, Oakley G Jr, Robert E. 1982. Valproic acid and spina bifida. Lancet 2: 1096.
13. Bowen SE, Battis JC, Mohammadi MH, Hannigan JH. 2005. Abuse pattern of gestational toluene exposure and early postnatal development in rats. Neurotoxicol Teratol 27: 105-116.
14. Bowen SE, Irtenkauf S, Hannigan JH, Stefanski AL. 2009. Alterations in rat fetal morphology following abuse patterns of toluene exposures. Reprod Toxciol 27: 161-169.
15. Brent RL. 1989. The effects of embryonic and fetal exposure to X-ray, microwaves, and ultrasound: Counseling the pregnant and nonpregnant patient about these risks. Semin Oncol 16: 347-368.
16. Brent RL. 2006. Counseling patients exposed to ionizing radiation during pregnancy. Rev Panam Salud Publica 20: 198-204.
17. Brown NA, Kao J, Fabro S. 1980. Teratogenic potential of valproic acid. Lancet 1: 660-661.
18. Buehler BA, Delimont D, van Waes M, Finnell RH. 1990. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 322: 1567-1572.
19. Buttar H. 1997. An overview of the influence of ACE inhibitors on fetal-placental circulation and perinatal development. Mol Cell Biochem 176: 61-71.
20. Camera G, Pregliasco P. 1992. Ear malformation in baby born to mother using tretinoin cream. Lancet 339: 687 only.
21. Carey JC, Martinez L, Balken E, Leen-Mitchell M, Robertson J. 2009. Determination of human teratogenicity by the astute clinician method: Review of illustrative agents and a proposal of guidelines. Birth Defects Res A Clin Mol Teratol 85: 63-68.
22. Centers for Disease Control. 1989. Rubella vaccination during pregnancy-United States, 1971-1988. MMWR 38: 289-293.
23. Chan WS, Anand S, Ginsberg JS. 2000. Anticoagulation of pregnant women with mechanical heart valves: A systematic review of the literature. Arch Intern Med 160: 191-196.
24. Chapa JB, Hibbard JU, Weber EM, Abramowicz JS, Verp MS. 2003. Prenatal diagnosis of methotrexate embryopathy. Obstet Gynecol 101: 1104-1107.
25. Chisholm CA, Chescheir NC, Kennedy M. 1997. Reversible oligohydramnios in a pregnancy with angiotensin-converting enzyme inhibitor exposure. Am J Perinatol 14: 511-513.
26. Clarren SK. 1981. Recognition of fetal alcohol syndrome. JAMA 245: 2436-2439.
27. Conte WR, McCammon CS, Christie A. 1945. Congenital defects following maternal rubella. Am J Dis Child 70: 301-306.
28. Cooper DS, Rivkees SA. 2009. Putting propylthiouracil in perspective. J Clin Endocrinol Metab 94: 1881-1882.
29. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer SD, Gideon PS, Hall K, Ray WA. 2006. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354: 2443-2451.
30. Cotrufo M, De Feo M, De Santo LS, Romano G, Della Corte A, Renzulli A, Gallo C. 2002. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 99: 35-40.
31. da Silva Dal Pizzol TS, Knop FP, Mengue SS. 2006. Prenatal exposure to misoprostol and congenital anomalies: Systematic review and meta analysis. Reprod Toxicol 22: 666-671.
32. da Silva Dal Pizzol TS, Sanseverino MTV, Mengue SS. 2008. Exposure to misoprostol and hormones during pregnancy and risk of congenital anomalies. Cad Saude Publica 24: 1447-1453.
33. De la Cruz E, Sun S, Vangvanichyakorn K, Desposito F. 1984. Multiple congenital malformations associated with maternal isotretinoin therapy. Pediatrics 74: 428-430.
34. DeCherney AH, Nathan L, Goodwin TM, Lauder N, editors. 2007. Current diagnosis and treatment: Obstetrics and gynecology. 10th edition. New York: McGaw-Hill.
35. DeSesso JM, Goeringer GC. 1992. Methotrexate-induced developmental toxicity in rabbits is ameliorated by 1-(p-tosyl)-3, 4, 4-trimethylimidazolidine, a functional analog for tetrahydrofolate-mediated one-carbon transfer. Teratology 45: 271-283.
36. Di Gianantonio E, Schaefer C, Mastroiacovo PP, Cournot MP, Benedicenti F, Reuvers M, Occupati B, Robert E, Bellemin B, Addis A, Arnon J, Clementi M. 2001. Adverse effects of prenatal methimazole exposure. Teratology 64: 262-266.
37. Diav-Citrin O, Ornoy A. 2002. Teratogen update: Antithyroid drugs-methimazole, carbimazole, and propylthiouracil. Teratology 65: 38-44.
38. Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. 2001. Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology 57: 321-324.
39. Diav-Citrin O, Shechtman S, Halberstadt Y, Finkel-Pekarsky V, Wajnberg R, Arnon J, Di Gianantonio E, Clementi M, Ornoy A. 2011. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol 31: 540-545.
40. Disaia PJ. 1966. Pregnancy and delivery of a patient with a Starr-Edwards mitral valve prosthesis. Obstet Gynecol 28: 469-472.
41. Dubick MA, Keen CL, Rucker RB. 1985. Elastin metabolism during perinatal lung development in the copper-deficient rat. Exp Lung Res 8: 227-241.
42. Edmonds LD, Oakley GP. 1990. Ebstein's anomaly and maternal lithium exposure during pregnancy. Teratology 41: 551-552.
43. Enders G. 1984. Varicella-zoster virus infection in pregnancy. Prog Med Virol 29: 166-196.
44. Enders G, Bolley I, Miller E, Cradock-Watson J, Ridehalgh M. 1994. Consequences of varicella and herpes zoster in pregnancy: Prospective study of 1739 cases. Lancet 343: 1548-1551.
45. Endres W. 1981. D-Penicillamine in pregnancy-To ban or not to ban? Klin Wochenschr 59: 535-537.
46. Eroǧlu E, Gökçil Z, Bek S, Ulaş UH, Odabaşi Z. 2008. Pregnancy and teratogenicity of antiepileptic drugs. Acta Neurol Belg 108: 53-57.
47. Fantel AG, Shepard TH, Newell-Morris LL, Moffett BC. 1977. Teratogenic effects of retinoic acid in pigtail monkeys (Macaca nemestrina) I. General features. Teratology 15: 65-71.
48. Feldkamp M, Carey JC. 1993. Clinical teratology counseling and consultation case report: Low dose methotrexate exposure in the early weeks of pregnancy. Teratology 47: 533-539.
49. Finnell RH, Dansky LV. 1991. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: Epidemiologic and experimental findings spanning three decades; 1: Animal studies. Reprod Toxicol 5: 281-299.
50. Florey C, Taylor D, Bolumar F, Kaminski M, Olsen J. editors. 1992. EUROMAC. A European concerted action: Maternal alcohol consumption and its relationship with the outcome of pregnancy and child development at 18 months. Int J Epidemiol 21:S38-S39.
51. Fonesca W, Alencar AJ, Mota FS, Coelho HL. 1991. Misoprostol and congenital malformations. Lancet 338: 56 only.
52. Forrest JM, Turnbull FM, Sholler GF. 2002. Gregg's congenital rubella patients 60 years later. Med J Aust 177: 664-667.
53. Gabbe SD, Simpson SL, Niebyl JR, Galan H, Goetzl L, Jauniaux ERM, Landon M, editors. 2007. Obstetrics: Normal and problem pregnancies. 5th edition. Philadelphia: Churchill Livingstone.
54. Ghafari A, Sanadgol H. 2008. Pregnancy after renal transplantation: Ten-year single-center experience. Transplant Proc 40: 251-252.
55. Goldberg JM, Falcone T. 1999. Effect of diethylstilbestrol on reproductive function. Fertil Steril 72: 1-7.
56. Golderg AB, Greensberg BS, Darney PD. 2001. Misoprostol and pregnancy. N Engl J Med 344: 38-46.
57. Gonzalez CH, Marques-Dias MJ, Kim CA, Sugayama SM, Da Paz JA, Huson SM, Holmes LB. 1998. Congenital abnormalities in Brazilian children associated with misoprostol misuse in the first trimester of pregnancy. Lancet 351: 1624-1627.
58. Goodwin TM. 1988. Toluene abuse and renal tubular acidosis in pregnancy. Obstet Gynecol 71: 715-718.
59. Gospe SM Jr, Saeed DB, Zhou SS, Zeman FJ. 1994. The effects of high-dose toluene on embryonic development in the rat. Pediatr Res 36: 811-814.
60. Gospe SM Jr, Zhou SS, Saeed DB, Zeman FJ. 1996. Developmental of a rat model of toluene-abuse embryopathy. Pediatr Res 40: 82-87.
61. Goulding EH, Pratt RM. 1986. Isotretinoin teratogenicity in mouse whole embryo culture. J Caniofac Genet Dev Biol 6: 99-112.
62. Gralla EJ, McIlhenny HM. 1972. Studies in pregnant rats, rabbits and monkeys with lithium carbonate. Toxicol Appl Pharmacol 21: 428-433.
63. Guignard JP, Burgener F, Calaine A. 1981. Persistent anuria in a neonate: a side effect of captopril? Int J Pediatr Nephrol 2: 133.
64. Hal EJ. 1991. Scientific view of low-level radiation risks. Radiographics 11: 509-518.
65. Hall BD. 1989. Warfarin embryopathy and urinary tract anomalies: Possible new association (letter). Am J Med Genet 34: 292-293.
66. Hall JG, Pauli RM, Wilson KM. 1980. Maternal and fetal squeal of anticoagulation during pregnancy. Am J Med 68: 122-140.
67. Hanson JW, Jones KL, Smith DW. 1976. Fetal alcohol syndrome-Experience with 41 patients. JAMA 235: 1458-1460.
68. Hanson JW, Smith DW. 1975. The fetal hydantoin syndrome. J Pediatr 87: 285-290.
69. Harlap S, Shiono PH. 1980. Alcohol, smoking and incidence of spontaneous abortions in the first and second trimester. Lancet 2: 173-176.
70. Harpey JP, Jaudon MC, Calvel JP, Galli A, Darbois Y. 1983. Cutis lax and low serum zinc after antenatal exposure to penicillamine. Lancet 2: 858 only.
71. Harrod MJE, Sherrod PS. 1981. Warfarin embryopathy in siblings. Obstet Gynecol 57: 673-676.
72. Harvey EB, Boyce JD Jr, Honey man M, Flannery JT. 1985. Prenatal X-ray exposure and childhood cancer in twins. N Engl J Med 312: 541-545.
73. Hendrickx AG, Nau H, Binkerd P, Rowland JM, Rowland JR, Cukierski MJ, Cukierski MA. 1988. Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: An interspecies comparison. Teratology 38: 329-345.
74. Herbst AL, Ulfelder H, Poskanzer DC. 1971. Adenocarcinoma of the vagina. Association of maternal stilbestreol therapy with tumor appearance in young women. N Engl J Med 284: 878-881.
75. Herndández-Díaz S, Mittendorf R, Holmes LB. 2010. Comparative safety of topiramate during pregnancy. Birth Defects Res (Part A) 88: 408 only.
76. Hiilesma VK, Brady AH, Granstron M-L, Teramo KAW. 1980. Valproic acid during pregnancy. Lancet 1: 883.
77. Hill AB. 1965. The environment and disease: Association or causation? Proc R Soc Med 58: 295-300.
78. Hitchcock PJ, MacKay HT, Wasserheit JN, editors. 1999. Sexually transmitted diseases and adverse outcomes of pregnancy. Washington, DC: American Society for Microbiology.
79. Hoberman AM, Deprospo JR, Lochry EA, Christian MS. 1990. Developmental toxicity study of orally administered lithium hypochlorite in rats. J Am Coll Toxicol 9: 367-379.
80. Hoeltzenbein M, Elefant E, Garayt Ornoy A, Clementi M, Manakova E, Merlob P, Rodríguez-Pinilla E, Rothuizen L, Smorlesi C, te Winkel B, de Santis M, Stephens S, Vial T, Weber-Schoendorfer C, Schaefer C. 2010. Maternal exposure to mycophenolate mofetil in pregnancy-Results of the ENTIS collaborative study. Reprod Toxicol 30: 228 only.
81. Holmes LB, Baldwin EJ, Smith CR, Habecker E, Glassman L, Wong SL, Wyszynski DF. 2008. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 70: 2152-2158.
82. Howe AM, Webster WS. 1992. The warfarin embryopathy: A rat model showing maxillonasal hypoplasia and other skeletal disturbances. Teratology 46: 379-390.
83. International Commission on Radiological Protection. 1986. Developmental effects of irradiation on the brain of the embryo and fetus. Ann ICRP 16: 1-43.
84. Irino M, Sanada H, Tashiro S, Yasuhira K, Takeda T. 1982. D-Penicillamine toxicity in mice. III. Pathological study of offspring of penicillamine-fed pregnant and lactating mice. Toxicol Appl Pharmacol 65: 273-285.
85. Iturbe-Alessio I, Fonseca MC, Mutchinik O, Santos MA, Zajarías A, Salazar E. 1986. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 315: 1390-1393.
86. Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Sahn D, Donnenfeld AE, Rieder M, Santelli R, Smythe J, Pastuszak A, Einarson T, Koren G. 1992. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 339: 530-533.
87. Janz D, Fuchs U. 1964. Are anti epileptic drugs harmful during pregnancy? Dtsch Med Wschr 89: 241-248.
88. Jefferies JA, Robboy SJ, O'Brien PC, Bergstralh EJ, Labarthe DR, Barnes AB, Noller KL, Hatab PA, Kaufman RH, Townsend DE. 1984. Structural anomalies of the cervix and vagina in women enrolled in the Diethylstilbestrol Adenosis (DESAD) Project. Am J Obstet Gynecol 148: 59-66.
89. Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, de Jong-van den Berg LTW, for the EUROCAT Antiepileptic Study Working Group. 2010. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 362: 2185-2193.
90. Jick SS, Terris BZ, Jick H. 1993. First trimester topical tretinoin. Lancet 341: 1181-1182.
91. Johansen KT. 1971. Lithium teratogenicity. Lancet 1: 1026-1027.
92. Jones KL. 1986. Fetal alcohol syndrome. Pediatr Rev 8: 122-126.
93. Jones KL, Smith DW, Ulleland CN, Streissguth P. 1973. Pattern of malformation in offspring of chronic alcoholic mothers. Lancet 301: 1267-1271.
94. Jones KL, Lacro RV, Johnson KA, Adams J. 1989. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 320: 1661-1666.
95. Jones KL, Johnson KA, Chambers CD. 1994. Offspring of women infected with varicella during pregnancy: A prospective study. Teratology 49: 29-32.
96. Jurand A. 1988. Teratogenic activity of lithium carbonate: An experimental update. Teratology 38: 101-111.
97. Källén B. 1988. Comments on teratogen update: Lithium. Teratology 38: 597 only.
98. Kalter H. 2003. Teratology in the 20th century. Environmental causes of congenital malformations in humans and how they were established. Neurotoxicol Teratol 25: 131-282.
99. Keen CL, Mark-Savage P, Lönnerdal B, Hurley LS. 1982. Teratogenesis and low copper status resulting from D-penicillamine in rats. Teratology 26: 163-165.
100. Keen CL, Mark-Savage P, Lönnerdal B, Hurley LS. 1983. Teratogenic effects of D-penicillamine in rats: Relation to copper deficiency. Drug Nutr Interact 2: 17-34.
101. Kerber IJ, Warr OS III, Richardson C. 1968. Pregnancy in a patient with a prosthetic mitral valve. Associated with a fetal anomaly attributed to warfarin sodium. JAMA 203: 223-225.
102. Kilbourn KH, Hess RA. 1982. Neonatal deaths and pulmonary dysplasia due to D-penicillamine in the rat. Teratology 26: 1-9.
103. Klieger-Grossmann C, Chitayat D, Lavigne S, Kao K, Garcia-Bournissen F, Quinn D, Lio V, Sermer M, Riordan S, Laskin C, Matok I, Gorodischer R, Chambers C, Levi A, Koren G. 2010. Prenatal exposure to mycophenolate mofetil: An updated estimate. J Obstet Gynaecol Can 32: 794-797.
104. Kochhar DM, Penner JD. 1987. Developmental effects of isotretinoin and 4-oxo-isotretinoin: The role of metabolism in teratogenicity. Teratology 36: 67-75.
105. Laforet EG, Lynch CL. 1947. Multiple congenital defects following maternal varicella. New Engl J Med 236: 534-537.
106. Lammer EJ. 1988. Embryopathy in infant conceived one year after termination of maternal etretinate. Lancet 2: 1080-1081.
107. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, Curry CJ, Fernhoff PM, Grix AW, Lott IT, Richard JM, Sun SC. 1985. Retinoic acid embryopthy. N Engl J Med 313: 837-841.
108. Laver M, Fairley KF. 1971. D-Penicillamine treatment in pregnancy. Lancet 1: 1019-1020.
109. Lemoine P. 2003. The history of alcoholic fetopathies (1997). J FAS Int 1: e2.
110. Lemoine P, Harrousseau H, Borteyru J-P, Menuet C. 1968. Les enfants des parents alcooliques: Anomalies observées: A propos de 127 cas. L'Ouest Med 21: 476-482.
111. Lemoine P, Harrousseau H, Borteyru J-P, Menuet C. 2003. Children of alcoholic parents-Observed anomalies: Discussion of 127 cases. Therap Drug Monit 25: 132-136.
112. Lennestål R, Otterblad Olausson P, Källén B. 2009. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 65: 615-625.
113. Lenz W. 1988. A short history of thalidomide embryopathy. Teratology 38: 203-215.
114. Linares A, Zarranz JJ, Rodriguez-Alarcon J, Diaz-Perez JL. 1979. Reversible cutis laxa due to maternal D-penicillamine treatment. Lancet 2: 43 only.
115. Lipson AH, Collins F, Webster WS. 1993. Multiple congenital defects associated with maternal use of topical tretinoin. Lancet 341: 1352-1353.
116. Loureiro KD, Kao KK, Jones KL, Alvarado S, Chavez C, Dick L, Felix R, Johnson D, Chambers CD. 2005. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet 136A: 117-121.
117. Marathe MR, Thomas GP. 1986. Embryotoxicity and teratogenicity of lithium carbonate in Wistar rat. Toxicol Lett 34: 115-120.
118. Malm H, Artama M, Gissler M, Klaukka T, Merilainen J, Nylander O, Paldan M, Palva E, Ritvanen A, Tyrkko K. 2008. First trimester use of ACE-inhibitors and risk of major malformations. Reprod Toxicol 26: 67.
119. Marecek Z, Graf M. 1976. Pregnancy in penicillamine-treated patients with Wilson's disease. N Engl J Med 295: 841-842.
120. Mark-Savage P, Keen CL, Hurley LS. 1983. Reduction by copper supplementation of teratogenic effects of D-penicillamine. J Nutr 113: 501-510.
121. Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC, for the NSG. 2006. In utero antiepileptic drug exposure: Fetal death and malformations. Neurology 67: 407-412.
122. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group. 2009. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 360: 1597-1605.
123. Melnick S, Cole P, Anderson D, Herbst A. 1987. Rates and risks of diethylstilbestrol related to clear cell adenocarcinoma of the vagina and cervix. N Engl J Med 316: 514-516.
124. Meltzer HJ. 1956. Congenital abnormalities due to attempted abortion with 4-aminopterylglutamic acid. JAMA 161: 1253 only.
125. Menser MA, Dods L, Harley JD. 1967. A twenty-five year follow-up of congenital rubella. Lancet 2: 1347-1350.
126. Merker HJ, Franke L, Günther T. 1975. The effect of D-penicillamine on skeletal development of rat fetuses. Nauyn Schmiedberg's Arch Pharm 287: 359-376.
127. Milham S Jr. 1985. Scalp defects in infants of mothers treated for hyperthyroidism with methimazole or carbimazole during pregnancy. Teratology 32: 321 only.
128. Milham S, Elledge W. 1972. Maternal methimazole and congenital defects in children. Teratology 5: 125 only.
129. Miller RW. 2004. How environmental hazards in childhood have been discovered: Carcinogens, teratogens, neurotoxicants, and others. Pediatrics 113: 945-951.
130. Miller E, Cradock-Watson JE, Pollack TM. 1982. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 2: 781-784.
131. Mjolnerod OK, Dommerud SA, Rasmussen K, Gjeruldsen ST. 1971. Congenital connective tissue defect probably due to D-penicillamine treatment in pregnancy. Lancet 1: 673-675.
132. Momotani N, Ito K, Hamada N, Ban Y, Nishikawa Y, Mimura T. 1984. Maternal hyperthyroidism and congenital malformation in the offspring. Clin Endocrinol (Oxf) 20: 695-700.
133. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ, Craig J. 2006. Malformation risks of antiepileptic drugs in pregnancy: A prospective study from the UK epilepsy and pregnancy register. J Neurol Neurosurg Psychiatry 77: 193-198.
134. Myint BA. 1984. D-penicillamine-induced cleft palate in mice. Teratology 30: 333-340.
135. Narotsky MG, Francis EZ, Kavlock RJ. 1994. Developmental toxicity and structure-activity relationships of aliphatic acids, including dose-response assessment of valproic acid in mice and rats. Fundam Appl Toxicol 22: 251-265.
136. Nau H. 2001. Teratogenicity of isotretinoin revisited: Species variation and the role of all-trans-retinoic acid. J Am Acad Dermatol 45: 183-187.
137. Niebyl JR, Blake DA, Freeman JM, Luff RD. 1979. Carbamazepine levels in pregnancy and lactation. Obstet Gynecol 53: 139-140.
138. Nora JJ, Nora AH, Toews WH. 1974. Lithium, Ebstein's anomaly, and other congenital heart defects. Lancet 2: 594-595.
139. Oakley C. 1983. Pregnancy in patients with prosthetic heart valves. Br Med J 286: 1680-1683.
140. Otake M, Schull WJ. 1984. In utero exposure to A-bomb radiation and mental retardation: A reassessment. Br J Radiol 57: 409-414.
141. Palmer JR, Herbst AL, Noller KL, Boggs DA, Troisi R, Titus-Ernstoff L, Hatch EE, Wise LA, Strohsnitter WC, Hoover RN. 2009. Urogenital abnormalities in men exposed to diethylstilbestrol in utero: A cohort study. Environ Health 8: 37. DOI: 10.1186/1476-069X-8-37.
142. Parkman PD. 1999. Making vaccination policy: The experience with rubella. Clin Infect Dis 28: S140-S146.
143. Parkman PD, Meyer HD, Kirschstein RL, Hoops HE. 1966. Attenuated rubella virus. I. Development and laboratory characterization. N Engl J Med 275: 569-574.
144. Paryani SG, Arvin AM. 1986. Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med 314: 1542-1546.
145. Pastaszak AL, Levy M, Schick B, Zuber C, Feldkamp M, Gladstone J, Bar-Levy F, Jackson E, Donnenfield A, Meschino W, Koren G. 1994. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 330: 901-905.
146. Pauli RM, Haun J. 1993. Intrauterine effects of coumarin derivatives. Dev Brain Dysfunc 6: 229-247.
147. Pearson MA, Hoyme HE, Seaver LH, Rimsza ME. 1994. Toluene embryopathy: Delineation of the phenotype and comparison with fetal alcohol syndrome. Pediatrics 93: 211-215.
148. Philip NM, Shannon C, Winkoff B. 2002. Misoprostol and Teratogenicity: Reviewing the Evidence. Report of a meeting at the Population Council.
149. Puhó EH, Szunyogh M, Métneki J, Czeizel AE. 2007. Drug treatment during pregnancy and isolated orofacial clefts in Hungary. Cleft Palate Craniofac J 44: 194-202.
150. Raghav S, Reutens D. 2007. Neurological sequelae of intrauterine warfarin exposure. J Clin Neurosci 14: 99-103.
151. REPROTOX®. 2011. Mycophenolate. Washington, DC: Reproductive Toxicology Center., last accessed April 16, 2011.
152. Robert E, Guibaud P. 1982. Maternal valproic acid and congenital neural tube defects. Lancet 2: 937.
153. Roebuck TM, Mattson SN, Riley EP. 1998. A review of the neuroanatomical findings in children with fetal alcohol syndrome or prenatal exposure to alcohol. Alcohol Clin Exp Res 22: 339-344.
154. Rosa FW. 1986. Teratogen update: Penicillamine. Teratology 33: 127-131.
155. Rosa FW. 1991. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 324: 674-677.
156. Rosas AF, Rijlaarsdam M, Buendia A, Zabal C, Kuri J, Granados N. 2000. The adult patient with Ebstein anomaly. Outcome in 72 unoperated patients. Medicine 79: 2736.
157. Saji H, Yamanaka M, Hagiwara A, Ijiri R. 2001. Losartan and fetal toxic effects. Lancet 357: 363 only.
158. Samren EB, van Duijn CM, Christiaens GCM, Hofman A, Lindhout D. 1999. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 46: 739-7746.
159. Samrén EB, van Duijn CM, Koch S, Hiilesmaa VK, Klepel H, Bardy AH, Mannagetta GB, Deichl AW, Gaily E, Granström ML, Meinardi H, Grobbee DE, Hofman A, Janz D, Lindhout D. 1997. Maternal use of antiepileptic drugs and the risk of major congenital malformations: A joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 38: 981-990.
160. Satgé D, Sasco AJ, Little J. 1998. Antenatal therapeutic drug exposure and fetal/neonatal tumours: Review of 89 cases. Paediatr Perinat Epidemiol 12: 84-117.
161. Schaefer C, Hannemann D, Meister R, Eléfant E, Paulus W, Vial T, Reuvers M, Robert-Gnansia E, Arnon J, De Santis M, Clementi M, Rodriguez-Pinilla E, Dolivo A, Merlob P. 2006. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost 95: 949-957.
162. Schmid BP. 1984. Monitoring of organ formation in rat embryos after in vitro exposure to azathioprine, mercaptopurine, methotrexate or cyclosporin A. Toxicology 31: 9-21.
163. Schonhofer PS. 1991. Brazil: Misuse of misoprostol as an abortifacient may induce malformations. Lancet 337: 1534-1535.
164. Schou M, Goldfield MD, Weinstein MR, Villeneuve A. 1973. Lithium and pregnancy. I. Report from the register of lithium babies. Br Med J 2: 135-136.
165. Schumacher H, Blake DA, Gillette JR. 1968a. Disposition of thalidomide in rabbits and rats. J Pharmacol Exp Ther 160: 201-211.
166. Schumacher H, Blake DA, Gurian JM, Gillette JR. 1968b. A comparison of the teratogenic activity of thalidomide in rabbits and rats. J Pharmacol Exp Ther 160: 189-200.
167. Sever J, White LR. 1968. Intrauterine viral infections. Annu Rev Med 19: 471-486.
168. Shapiro L, Pastuszak A, Cutro G, Koren G. 1997. Safety of first-trimester exposure to topical tretinoin: Prospective cohort study. Lancet 350: 1143-1144.
169. Shaul WL, Hall JG. 1977. Multiple congenital anomalies associated with oral anticoagulants. Am J Obstet Gynecol 127: 191-198.
170. Shaw EB, Steinbach HL. 1968. Aminopterin-induced fetal malformations: Survival of infant after attempted abortion. Am J Dis Child 115: 477-482.
171. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. 2006. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82: 1698-1702.
172. Skalko RG, Gold MP. 1974. Teratogenicity of methotrexate in mice. Teratology 9: 159-164.
173. Smithberg M, Dixit PK. 1982. Teratogenic effects of lithium in mice. Teratology 26: 239-246.
174. Solomon L, Abrams G, Dinner M, Berman L. 1977. Neonatal abnormalities associated with D-penicillamine treatment during pregnancy. N Engl J Med 296: 54-55.
175. Song J. 2000. The use of misoprostol in obstetrics and gynecology. Obstet Gynecol Surv 55: 503-510.
176. Steffek AJ, Verrusio AC, Watkins CA. 1972. Cleft palate in rodents after maternal treatment with various lathyrogenic agents. Teratology 5: 33-40.
177. Stern RS, Rosa F, Baum C. 1984. Isotretinoin and pregnancy. J Am Acad Dermatol 10: 851-854.
178. Strandberg-Larsen K, Nielsen NR, Gronbaek M, Andersen PK, Olsen J, Andersen AN. 2008. Binge drinking in pregnancy and risk of fetal death. Obstet Gynecol 111: 602-609.
179. Streissguth AP. 1978. Fetal alcohol syndrome: An epidemiologic perspective. Am J Epidemiol 107: 467-478.
180. Svirsky R, Rozovski U, Vaknin Z, Pansky M, Schneider D, Halperin R. 2009. The safety of conception occurring shortly after methotrexate treatment of an ectopic pregnancy. Reprod Toxicol 27: 85-87.
181. Szabo KT. 1970. Teratogenic effect of lithium carbonate in the foetal mouse. Nature 225: 73-75.
182. Tabacova S, Little R, Tsong Y, Vega A, Kimmel CA. 2003. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf 12: 633-646.
183. Thiersch JB. 1952. Therapeutic abortions with folic acid antagoinist 4-amino-pteroylglutamic acid (4 amino P.G.A.) administered by oral route. Am J Obstet Gynecol 63: 1298-1304.
184. Thiersch JB, Phillips FS. 1950. Effect of 4-aminopteroylglutamic acid (aminopterin) on early pregnancy. Proc Soc Exp Biol Med 74: 204-208.
185. Toutant C, Lippmann S. 1979. Fetal solvents syndrome. Lancet 1: 1356.
186. Kesmodel U, Wisborg K, Olsen SF, Henriksen TB, Secher NJ. 2002. Moderate alcohol intake during pregnancy and the risk of still birth and death in the first year. Am J Epidemiol 155: 305-3331.
187. Usta IM, Nassar AH, Yunis KA, Abu-Musa AA. 2007. Methotrexate embryopathy after therapy for misdiagnosed ectopic pregnancy. Int J Gynaecol Obstet 99: 253-255.
188. Vajda FJ, Hitchcock A, Graham J, Solinas C, O'Brien TJ, Lander CM, Eadie MJ. 2006. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur J Neurol 13: 645-654.
189. Vajda FJ, Hitchcock A, Graham J, O'Brien T, Lander C, Eadie M. 2007. The Australian Register of Antiepileptic Drugs in Pregnancy: The first 1002 pregnancies. Aust NZ J Obstet Gynaecol 47: 468-474.
190. Van Dijke CP, Heydendael RJ, De Kleine MJ. 1987. Methimazole, carbimazole, and congenital skin defects. Ann Intern Med 106: 60-61.
191. Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VF, Sugayam SL, Albano L, Llerena JC, Almeida JC, Duarte A, Calvacanti DP, Goloni-Bertollo E, Conte A, Koren G, Addis A. 2000. Prenatal exposure to misoprostol and vascular disruption defects: A case-control study. Am J Med Genet 95: 302-306.
192. Verloes A, Frikiche A, Gremillet C, Paquay T, Decortis T, Rigo J, Senterre J. 1990. Proximal phocomelia and radial ray aplasia in fetal valproic acid syndrome. Eur J Pediatr 149: 266-267.
193. Wallpole I, Zubrick S, Pontre J. 1990. Is there a fetal effect with low to moderate alcohol use before or during pregnancy? J Epidemiol Community Health 44: 297-301.
194. Wardrop D, Keeling D. 2008. The story of the discovery of heparin and warfarin. Br J Haematol 141: 757-763.
195. Warkany J, Beaudry PH, Hornstein S. 1959. Attempted abortion with aminopterin (4-aminopterylglutamic acid). AMA J Dis Child 97: 274-281.
196. Webster WS. 1998. Teratogen update: Congenital rubella. Teratology 58: 13-23.
197. Weinstein MR, Goldfield MD. 1975. Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry 132: 529-531.
198. Wesselhoeft C. 1947. Rubella (German measles). N Engl J Med 236: 978-988.
199. Wilkins-Haug L. 1997. Teratogen update: Toluene. Teratology 55: 145-151.
200. Wilkins-Haug L, Gabow PA. 1991. Toluene abuse during pregnancy: Obstetric complications and perinatal outcomes. Obstet Gynecol 77: 504-509.
201. Windham GC, Fenster L, Hopkins B, Swan SH. 1995. The association of moderate maternal and paternal alcohol consumption with birthweight and gestational age. Epidemiology 6: 591-597.
202. Wing DA, Millar LK, Koonings PP, Montoro MN, Mestman JH. 1994. A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. Am J Obstet Gynecol 170: 90-95.
203. Wright TL, Hoffman LH, Davies J. 1971. Teratogenic effects of lithium in rats. Teratology 4: 151-155.
204. Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB, Antiepileptic Drug Pregnancy Registry. 2005. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 64: 961-965.
205. Ylagan LR, Budorick NE. 1992. Radial ray aplasia in utero: A prenatal finding associated with valproic acid exposure. J Ultrasound Med 13: 408-411.
206. Zalzstein E, Koren G, Einarson T, Freedom RM. 1990. A case-control study on the association between first trimester exposure to lithium and Ebstein's anomaly. Am J Cardiol 65: 817-818.
207. Zamenhof S. 1985. Differential effects of antifolate on the development of brain parts in chick embryos. Growth 49: 28-33.
208. Zeldis JB, Williams BA, Thomas SD, Elsayed ME. 1999. S.T.E.P.S.: A comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 21: 319-330.